Vir Biotechnology, Inc.
Vir Biotechnology, Inc. (VIR) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
vir · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Vir Biotechnology, Inc. (VIR) measures how much investors pay for each dollar of the company's trailing earnings. VIR's current PE ratio of N/A is calculated by dividing its stock price of $8.45 by its TTM earnings per share of -$3.00.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2017 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Vir Biotechnology, Inc.You VIR | $1.4B | N/A | — | -$3.00 |
 Day One Biopharmaceuticals, Inc. DAWN | $2.2B | N/A | — | -$1.04 |
 Ginkgo Bioworks Holdings, Inc. DNA | $528M | N/A | — | -$5.64 |
 Geron Corporation GERN | $725M | N/A | — | -$0.13 |
 Iovance Biotherapeutics, Inc. IOVA | $1.4B | N/A | — | -$1.09 |
 Kura Oncology, Inc. KURA | $760M | N/A | — | -$3.18 |
 LENZ Therapeutics, Inc. LENZ | $211M | N/A | — | -$2.85 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-3.16 | — | |
2024-12-31 FY2024 | — | $-3.83 | — | |
2023-12-31 FY2023 | — | $-4.59 | — | |
2022-12-31 FY2022 | 6.51x | $3.89 | -36.8% | |
2021-12-31 FY2021 | 10.29x | $4.07 | — | |
2020-12-31 FY2020 | — | $-2.51 | — | |
2019-12-31 FY2019 | — | $-1.62 | — | |
2018-12-31 FY2018 | — | $-1.20 | — | |
2017-12-31 FY2017 | — | $-10.02 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Vir Biotechnology, Inc. (VIR) measures how much investors pay for each dollar of the company's trailing earnings. VIR's current PE ratio of N/A is calculated by dividing its stock price of $8.45 by its TTM earnings per share of -$3.00.
Frequently asked questions
VIR pe ratio · 6 questionsVIR's current PE ratio is N/A as of 2026-06-08, based on a stock price of $8.45 and TTM EPS of -$3.00. Data sourced from Financial Modeling Prep via VIR's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Vir Biotechnology, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08